Dose Escalated Radiation Therapy for Glioblastoma Multiforme: An International Systematic Review and Meta-Analysis of 22 Prospective Trials
Journal Article
·
· International Journal of Radiation Oncology, Biology and Physics
- Department of Radiation Oncology, Virginia Commonwealth University Health System, Richmond (United States)
- Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York (United States)
- Department of Public Health Sciences, Penn State University, Hershey (United States)
- Department of Radiation Oncology, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus (United States)
Limited evidence is available on the utility of dose-escalated radiation therapy (DE-RT) with or without temozolomide (TMZ) versus standard-of-care radiation therapy (SoC-RT) for patients with newly diagnosed glioblastoma multiforme. We performed a systematic review/meta-analysis to compare overall survival (OS) and progression-free survival (PFS) between DE-RT and SoC-RT.
- OSTI ID:
- 23200982
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 2 Vol. 111; ISSN IOBPD3; ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Radiation Therapy Dose Escalation for Glioblastoma Multiforme in the Era of Temozolomide
Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment
Phase 1/2 Trials of Temozolomide, Motexafin Gadolinium, and 60-Gy Fractionated Radiation for Newly Diagnosed Supratentorial Glioblastoma Multiforme: Final Results of RTOG 0513
Journal Article
·
Fri Nov 14 23:00:00 EST 2014
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:22420477
Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment
Journal Article
·
Sun Apr 15 00:00:00 EDT 2018
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:23082767
Phase 1/2 Trials of Temozolomide, Motexafin Gadolinium, and 60-Gy Fractionated Radiation for Newly Diagnosed Supratentorial Glioblastoma Multiforme: Final Results of RTOG 0513
Journal Article
·
Wed Apr 01 00:00:00 EDT 2015
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:22458669